Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shijiazhuang
Clinical trial register · China

Clinical Trials in Shijiazhuang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Shijiazhuang 43 Hebei 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hebei Medical University Fourth Hospital43 Novartis Pharmaceuticals12 BeOne Medicines9 Pfizer8 Bristol-Myers Squibb8 Clear sponsor filter
Site location
Shijiazhuang43 Hebei1
All 2 locations
Target enrolment
to

Trials with a site in Shijiazhuang

43 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
33
Shijiazhuang
2026-10
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
48
Shijiazhuang
2026-08-15
Not yet open
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
NCT07697040Esophageal Squamous Cell Carcinoma
DrugBecotatug Vedotin
Hebei Medical University Fourth Hospital
Phase 1
12
Shijiazhuang
2026-07-01
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
38
Shijiazhuang
2026-06-01
Not yet open
Hebei Medical University Fourth Hospital
Phase 2/3
408
Shijiazhuang
2026-05-20
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
100
Shijiazhuang
2026-05
Recruiting
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
NCT07448077Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2
128
Shijiazhuang
2026-03-01
Not yet open
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
NCT07410611Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
DrugBefotertinib
Hebei Medical University Fourth Hospital
Phase 2
84
Shijiazhuang
2026-02-10
Recruiting
Hebei Medical University Fourth Hospital
Observational
150
Shijiazhuang
2026-01-17
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
39
Shijiazhuang
2025-09-28
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
25
Shijiazhuang
2025-09-26
Recruiting
Hebei Medical University Fourth Hospital
Observational
2,000
Shijiazhuang
2025-09-15
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-09-12
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
142
Shijiazhuang
2025-09-01
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
36
Shijiazhuang
2025-08-10
Not yet open
Hebei Medical University Fourth Hospital
Phase 4
40
Shijiazhuang
2025-07-01
Recruiting
Hebei Medical University Fourth Hospital
Observational
200
Shijiazhuang
2025-06-18
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
128
Shijiazhuang
2025-05-15
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-05-15
Not yet open
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
NCT06903871Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
DrugsJS001·Toripalimab
Hebei Medical University Fourth Hospital
Phase 2
190
Shijiazhuang
2025-04-01
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
64
Shijiazhuang
2025-03-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-03-01
Not yet open
Hebei Medical University Fourth Hospital
Phase 2
51
Shijiazhuang
2024-11-01
Recruiting
Hebei Medical University Fourth Hospital
Observational
420
Shijiazhuang
2024-09-13
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
30
Shijiazhuang
2024-08-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
182
Shijiazhuang
2024-04-30
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
67
Shijiazhuang
2024-04-01
Active, closed
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2024-02-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 4
100
Shijiazhuang
2024-01-02
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
173
Shijiazhuang
2024-01-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
144
Shijiazhuang
2023-09-30
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
58
Shijiazhuang
2023-06-01
Recruiting
Hebei Medical University Fourth Hospital
Not applicable
20
Shijiazhuang
2023-05-01
Recruiting
Minimally Residual of Esophageal Cancer 001
NCT05952661Esophageal Carcinoma, Minimal Residual Disease
Hebei Medical University Fourth Hospital
Observational
56
Shijiazhuang
2023-02-22
Recruiting
Hebei Medical University Fourth Hospital
Phase 1
100
Shijiazhuang
2023-01-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
80
Shijiazhuang
2022-05-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 4
75
Shijiazhuang
2022-03-31
Recruiting
Hebei Medical University Fourth Hospital
Observational
620
Shijiazhuang
2020-11-19
Active, closed
Hebei Medical University Fourth Hospital
Phase 2/3
113
Shijiazhuang
2020-03-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
520
Shijiazhuang
2019-11-20
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
414
Shijiazhuang
2019-11-20
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
202
Shijiazhuang
2019-04-24
Active, closed
Hebei Medical University Fourth Hospital
Observational
1,000
Shijiazhuang
2015-01-01
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/shijiazhuang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Shijiazhuang that also match the filters currently applied.

How many clinical trials are recruiting in Shijiazhuang?

29 of the 43 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 11 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shijiazhuang), 43 studies
PhaseStudiesRecruitingShare
Phase 2281965.1%
Observational7616.3%
Phase 4327%
Phase 1214.7%
Phase 2/3204.7%
Not applicable112.3%

Most active sponsors

Lead sponsors with the most studies (Shijiazhuang)
Lead sponsorStudiesRecruiting
Hebei Medical University Fourth Hospital4329
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.